Patents by Inventor Tadashi Nakajima

Tadashi Nakajima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11403816
    Abstract: A three-dimensional map generation system (500) generates three-dimensional map information (11) by using measured data acquired by a measurement vehicle (200) moving in a measurement area (50). A determination unit (120) determines, from the measurement area (50), a data shortage area where measured data for generating the three-dimensional map falls short, based on first measured data (20) transmitted from the measurement vehicle (200). A generation unit (130) generates interpolated data which interpolates three-dimensional map information of a defective area with a NURBS curve so that a lateral G, which is centrifugal force in a lateral direction applied to a traveling vehicle traveling a road in the defective area at a traveling speed, is equal to or less than a predefined threshold (12).
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: August 2, 2022
    Assignees: Mitsubishi Electric Corporation, Dynamic Map Platform Co., Ltd.
    Inventors: Toshiharu Suzuki, Tsutomu Nakajima, Tadashi Ozawa
  • Patent number: 9561502
    Abstract: A conductive polymer material which can achieve longer operating life by improving resistance stability at the time of performing continuous conduction, a method for producing the conductive polymer material, and an image forming device member are provided. A conductive polymer material containing a quaternary ammonium base incorporated in a main chain of a polymer material as an electrolyte cation, and an alkyl sulfate radical as an electrolyte anion.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: February 7, 2017
    Assignee: BRIDGESTONE CORPORATION
    Inventors: Tadashi Nakajima, Hirotaka Tagawa
  • Publication number: 20150352542
    Abstract: A conductive polymer material which can achieve longer operating life by improving resistance stability at the time of performing continuous conduction, a method for producing the conductive polymer material, and an image forming device member are provided. A conductive polymer material containing a quaternary ammonium base incorporated in a main chain of a polymer material as an electrolyte cation, and an alkyl sulfate radical as an electrolyte anion.
    Type: Application
    Filed: January 10, 2014
    Publication date: December 10, 2015
    Applicant: BRIDGESTONE CORPORATION
    Inventors: Tadashi NAKAJIMA, Hirotaka TAGAWA
  • Patent number: 9096782
    Abstract: The present invention provides a polyester, a polyester composition and a pressure-sensitive adhesive composition capable of obtaining a pressure-sensitive adhesive which is global-environmentally friendly and is excellent in pressure-sensitive adhesion properties, using a plant-derived raw material; and a pressure-sensitive adhesive layer and a pressure-sensitive adhesive sheet which can be obtained by using the same. A polyester of the present invention is a polyester comprising at least a lactic acid unit, a dibasic acid unit and a glycol unit, wherein the dibasic acid unit contains dimer acid, and the polyester has a glass transition temperature as measured at a temperature rising rate of 20° C./minute using a differential scanning calorimeter, of ?70 to ?20° C., a weight average molecular weight of 20,000 to 300,000 and a hydroxyl value of 1 to 100 mgKOH/g.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: August 4, 2015
    Assignees: NITTO DENKO CORPORATION, Toyo Boseki Kabushiki Kaisha
    Inventors: Hitoshi Takahira, Satomi Yoshie, Tadashi Nakajima, Daiki Funaoka, Katsuya Shimeno
  • Patent number: 8232308
    Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: July 31, 2012
    Assignees: UBE Industries, Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Publication number: 20120040994
    Abstract: A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs including (i) a Rho kinase inhibitor selected from the group consisting of (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and 1-(5-isoquinolinesulfonyl)-homopiperazine, or a salt thereof and (ii) a prostaglandin which is latanoprost or a salt of latanoprost, and (iii) optionally a pharmaceutically acceptable carrier. A therapeutic composition for treating glaucoma or for reducing intraocular pressure containing a combination of pharmaceutically effective amounts of drugs comprising (i) a Rho kinase which is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a slat thereof and (ii) a prostaglandin which is isopropyl unoprostone or a salt thereof, and (iii) optionally a pharmaceutically acceptable carrier.
    Type: Application
    Filed: October 25, 2011
    Publication date: February 16, 2012
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi NAKAJIMA, Takeshi MATSUGI, Hideaki HARA
  • Publication number: 20110263638
    Abstract: A therapeutic agent for glaucoma including a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a ?-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the ?-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. A method of treating glaucoma including administering effective amounts of a Rho kinase inhibitor and a ?-blocker to a patient, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the ?-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.
    Type: Application
    Filed: June 30, 2011
    Publication date: October 27, 2011
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Patent number: 7972612
    Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: July 5, 2011
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Publication number: 20110135924
    Abstract: The present invention provides a polyester, a polyester composition and a pressure-sensitive adhesive composition capable of obtaining a pressure-sensitive adhesive which is global-environmentally friendly and is excellent in pressure-sensitive adhesion properties, using a plant-derived raw material; and a pressure-sensitive adhesive layer and a pressure-sensitive adhesive sheet which can be obtained by using the same. A polyester of the present invention is a polyester comprising at least a lactic acid unit, a dibasic acid unit and a glycol unit, wherein the dibasic acid unit contains dimer acid, and the polyester has a glass transition temperature as measured at a temperature rising rate of 20° C./minute using a differential scanning calorimeter, of ?70 to ?20° C., a weight average molecular weight of 20,000 to 300,000 and a hydroxyl value of 1 to 100 mgKOH/g.
    Type: Application
    Filed: August 5, 2009
    Publication date: June 9, 2011
    Applicants: NITTO DENKO CORPORATION, TOYO BOSEKI KABUSHIKI KAISHA
    Inventors: Hitoshi Takahira, Satomi Yoshie, Tadashi Nakajima, Daiki Funaoka, Katsuya Shimeno
  • Publication number: 20110039891
    Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.
    Type: Application
    Filed: October 20, 2010
    Publication date: February 17, 2011
    Applicants: UBE INDUSTRIES, LTD., SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Patent number: 7855222
    Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: December 21, 2010
    Assignees: UBE Industries, Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Publication number: 20100063060
    Abstract: A combination of a Rho kinase inhibitor and a prostaglandin as a therapeutic agent for treating glaucoma. The actions of reducing intraocular pressure are complemented and/or enhanced by combining a Rho kinase inhibitor with a prostaglandin. Each of the Rho kinase inhibitor and the prostaglandin can be administered in combination or in a mixture.
    Type: Application
    Filed: October 16, 2009
    Publication date: March 11, 2010
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Publication number: 20100041671
    Abstract: A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin.
    Type: Application
    Filed: October 16, 2009
    Publication date: February 18, 2010
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Publication number: 20090264468
    Abstract: A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the following formula or a pharmaceutically acceptable salt thereof: , wherein the ring X is a benzene ring or a pyridine ring; R1 and R2 are hydrogen or alkyl or together form a cycloalkene ring; R3 is hydrogen, substituted alkyl, unsubstituted alkenyl, carboxyl or an ester or an amide thereof, amino or a cyano; R4 is hydrogen, hydroxyl, substituted or unsubstituted alkoxy, unsubstituted alkenyloxy, unsubstituted cycloalkyloxy, substituted or unsubstituted alkyl, unsubstituted alkenyl, unsubstituted cycloalkyl, amino, substituted or unsubstituted alkylamino, nitro, cyano or a monocyclic heterocycle; and R5 is a halogen atom or a hydrogen atom.
    Type: Application
    Filed: June 19, 2009
    Publication date: October 22, 2009
    Applicants: UBE INDUSTRIES, LTD., SANTEN PHARMACEUTICALS CO., LTD.
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Patent number: 7563906
    Abstract: An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: July 21, 2009
    Assignees: Ube Industries, Ltd., Santen Pharmaceutical Co., Ltd.
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Publication number: 20070129404
    Abstract: An object of the present invention is to create a novel indazole derivative useful as a drug and to find a novel pharmacological action of the derivative. The compound of the present invention is represented by the formula [I] and has an excellent Rho kinase inhibiting action. In the formula, a ring X is a benzene ring or a pyridine ring; R1 and R2 are H or alkyl; R3 and R4 are halogen, H, OH, alkoxy, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, aryloxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, carboxy, hydrocarbonyl, alkylcarbonyl, etc.; and R5 is halogen atom, H, OH, alkoxy, aryloxy, alkyl or aryl. Each group can be substituted.
    Type: Application
    Filed: October 15, 2004
    Publication date: June 7, 2007
    Inventors: Masahiko Hagihara, Ken-ichi Komori, Hidetoshi Sunamoto, Hiroshi Nishida, Takeshi Matsugi, Tadashi Nakajima, Masakazu Hatano, Kazutaka Kido, Hideaki Hara
  • Publication number: 20060052367
    Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor having a novel action and a ?-blocker as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with the ?-blocker. For the administration mode, each drug can be administered in combination or in mixture.
    Type: Application
    Filed: November 17, 2003
    Publication date: March 9, 2006
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masakazu Hatano, Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Publication number: 20050245509
    Abstract: A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor and prostaglandins as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and/or enhanced each other by combining the Rho kinase inhibitor with prostaglandins. For the administration mode, each drug can be administered in combination or in mixture.
    Type: Application
    Filed: August 29, 2003
    Publication date: November 3, 2005
    Applicant: SANTEN PHARMACECUTICAL CO., LTD.
    Inventors: Tadashi Nakajima, Takeshi Matsugi, Hideaki Hara
  • Patent number: 6814892
    Abstract: An ethylene propylene rubber foam which comprises as the crude rubber, an ethylene propylene rubber having an iodine value of 35 to 45 and a Mooney viscosity ML1+4 at 100° C. of 20 to 50, and which has less compression set and is suitable as a material for a transfer member, a primary transfer member, a secondary transfer member, a cleaning member for image formation bodies, a bias member, a backup member, etc.; an electroconductive ethylene propylene rubber foam which comprises as the crude rubber, an ethylene propylene rubber having an iodine value of 35 to 45 and a Mooney viscosity ML1+4 at 100° C.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: November 9, 2004
    Assignee: Bridgestone Corporation
    Inventors: Chikara Yamada, Toshiyuki Osaki, Tadashi Nakajima, Takahiro Kawagoe
  • Publication number: 20030201425
    Abstract: An ethylene propylene rubber foam which comprises as the crude rubber, an ethylene propylene rubber having an iodine value of 35 to 45 and a Mooney viscosity ML1+4 at 100° C. of 20 to 50, and which has less compression set and is suitable as a material for a transfer member, a primary transfer member, a secondary transfer member, a cleaning member for image formation bodies, a bias member, a backup member, etc.; an electroconductive ethylene propylene rubber foam which comprises as the crude rubber, an ethylene propylene rubber having an iodine value of 35 to 45 and a Mooney viscosity ML1+4 at 100° C.
    Type: Application
    Filed: April 11, 2003
    Publication date: October 30, 2003
    Applicant: Bridgestone Corporation
    Inventors: Chikara Yamada, Toshiyuki Osaki, Tadashi Nakajima, Takahiro Kawagoe